Beaird Harris Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.4K Hold
33
﹤0.01% 353
2026
Q1
$14.7K Hold
33
﹤0.01% 339
2025
Q4
$15K Hold
33
﹤0.01% 368
2025
Q3
$12.9K Buy
33
+5
+18% +$2.09K ﹤0.01% 365
2025
Q2
$12.5K Buy
28
+14
+100% +$6.45K ﹤0.01% 365
2025
Q1
$6.79K Buy
14
+5
+56% +$2.33K ﹤0.01% 365
2024
Q4
$3.63K Hold
9
﹤0.01% 395
2024
Q3
$4.19K Hold
9
﹤0.01% 387
2024
Q2
$4.22K Hold
9
﹤0.01% 463
2024
Q1
$3.76K Hold
9
﹤0.01% 418
2023
Q4
$3.66K Buy
+9
New +$3.33K ﹤0.01% 412
2023
Q1
Sell
-62
Closed -$17.9K 744
2022
Q4
$17.9K Buy
+62
New +$18.9K ﹤0.01% 270

Other funds holding VRTX

Beaird Harris Wealth Management's VRTX Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 33 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Beaird Harris Wealth Management first reported a position in VRTX in Q4 2022 and has held it in 12 quarters since. The position peaked at $17.9K in Q4 2022. 299 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Beaird Harris Wealth Management held 33 shares of Vertex Pharmaceuticals worth $16.4K as of Q2 2026.
  • Beaird Harris Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #353 holding.
  • Beaird Harris Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • Beaird Harris Wealth Management's Vertex Pharmaceuticals position peaked at $17.9K in Q4 2022.
  • 299 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.